Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers

NCT05360680 is registered in ClinicalTrials.gov with Cue Biopharma as lead sponsor.

NCT NCT05360680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05360680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers
Lead sponsor
Cue Biopharma
Phase
Phase 1
Overall status
Completed
Start date
June 14, 2022
Completion date
March 12, 2025
Enrollment
42 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, gastric cancer, ovarian cancer, pancreatic cancer